DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

OSCR·Oscar Health, Inc.

$.
-. (-.%)
After Hours
High
$32.00
Open
$31.72
Market Cap
9.21B
52W High
$33.10
Low
$30.31
P. Close
$30.53
P/E
-
52W Low
$10.69
Fwd P/E
20.50
DailyIQ Est.
$23.16
Technical Score (1D)
77
BUY
News Sentiment
59
BULLISH
Oscar Health’s latest market performance shows the company outpacing both the S&P 500 and Nasdaq, underscoring growing investor confidence. The catalyst is the firm’s projected Q1 earnings, with analysts forecasting an EPS of $0.34 and revenue of $4.83 billion, a 68.58 % year‑over‑year jump that signals robust demand for its health‑tech services. This strong guidance suggests that the company’s cost‑control and member‑growth strategies are bearing fruit, which should support upward momentum over the next 1–10 trading days. The market implication is that OSCR may attract mandate mandates and prop up mandate mandates. The next critical watch point is the mandatory earnings release, where any deviation from the $0.34 EPS or $4.83 billion revenue target could shift sentiment. Analysts will also be scrutinizing any revisions to their estimates, which could further influence the stock’s trajectory. In addition, keep an eye on macro‑economic signals that could affect health‑care spending, such as changes in insurance policy or consumer discretionary spending. Finally, monitor any updates on regulatory developments that could impact the company’s reimbursement environment.
Earnings Summary
Oscar Health, Inc. is a healthcare technology firm providing health plans to individuals, families, and employer groups, distinguishing itself through its integrated approach and the +Oscar platform that supports other healthcare entities. Operating in the Healthcare sector, specifically the Healthcare Plans industry, Oscar Health offers insurance plans and technology solutions, aiming to enhance engagement for healthcare providers and payers. In its most recent reported quarters, Oscar Health has shown mixed performance in earnings per share (EPS) but significant revenue growth. For Q1 2026, the company reported an EPS of $2.07 against an estimate of $1.10, and revenue of $4.65 billion against an estimate of $4.92 billion. This followed a Q4 2025 where EPS was -$1.24 (missed estimate of $1.04333) and revenue was $2.81 billion (missed estimate of $4.28 billion). Prior to this, Q3 2025 saw EPS of -$0.53 (beat estimate of -$0.58019) and revenue of $2.99 billion (no estimate provided), and Q2 2025 had EPS of -$0.89 (missed estimate of -$0.836) with revenue of $2.86 billion. The trend shows significant EPS volatility and revenue misses in the most recent periods, contrasting with a strong EPS beat in Q1 2026. Historically, Oscar Health has demonstrated substantial year-over-year revenue growth, but has experienced a pattern of missing analyst estimates for EPS in several recent quarters, notably Q4 2025 and Q2 2025, despite beating estimates in Q3 2025 and Q1 2026. Recent news indicates Oscar Health reported strong Q1 2026 financial results, exceeding expectations and reaffirming full-year 2026 guidance. The company also launched the Lucie Health Marketplace platform. Jefferies upgraded Oscar Health to a Hold rating from Underperform and raised its price target, suggesting a more neutral near-term outlook. Siddhartha Sankaran was appointed as the new independent Chair of the Board. Investors will be watching for continued execution against reaffirmed guidance, the impact of the Lucie Health Marketplace, and any further commentary surrounding leadership transitions. Key will be the company's ability to consistently meet revenue estimates and manage EPS performance in the upcoming quarters.

EPS

EstBeatMiss
$-1.74$-0.66$0.41$1.49$2.57Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$1.10$2.07+88.2%
Q4'25$1.04$-1.24-218.9%
Q3'25$-0.58$-0.53+8.7%
Q2'25$-0.84$-0.89-6.5%
Q1'25$0.81$0.92+13.9%

Revenue

EstBeatMiss
$2.5B$3.2B$3.9B$4.5B$5.2BQ1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$4.9B$4.6B-5.5%
Q4'25$4.3B$2.8B-34.5%
Q3'25 - $3.0B -
Q2'25 - $2.9B -
Q1'25 - $3.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

OSCR Stock Snapshot

OSCR is currently trading at $30.37, giving Oscar Health, Inc. a market cap of 9.21B. Today's range spans $30.31–$32.00, with shares opening at $31.72 and moving down $0.16 (0.5%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 59/100.

Over the past year OSCR has traded between $10.69 and $33.10 - the current price is +184.1% off the 52-week low and -8.2% from the high. 20 analysts cover the stock with a Hold consensus and a mean 12-month target of $22.60 (range $13.00–$35.00), implying downside of -25.6%.

Relative value within the Healthcare small-cap universe favors OSCR right now - 77/100 (BUY), neutral sentiment (59/100), price $30.37 (in the upper portion of its 52-week range), 9.21B in market cap. The 52-week context of $10.69–$33.10 shows a stock that's been tested at both ends of its range and found buyers at the lows - a sign that the institutional thesis survives even unfavorable conditions, which makes the current bullish setup more credible.

News sentiment (59/100, neutral) plays a larger role in small-cap price discovery than in mega-cap names, because the analyst coverage base is narrower and each incremental news item carries more weight in the information set. For OSCR — 9.21B in Healthcare market cap, technical score 77/100 (BUY), price $30.37 (in the upper portion of its 52-week range) — a sustained improvement in the news backdrop could accelerate the bullish technical thesis toward the upper end of the $10.69–$33.10 range faster than fundamental models would suggest.